Corcept Therapeutics | CORT - Ebitda


Corcept Therapeutics reported $27.14M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
ANI Pharmaceuticals USD 59.6M 5.52M Sep/2025
Ardelyx USD 5.57M 17.44M Sep/2025
Aurora Cannabis CAD 15.37M 26.8M Sep/2025
BioMarin Pharmaceutical USD -5.26M 300.71M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Canopy Growth CAD 16.62M 38.45M Sep/2025
Corcept Therapeutics USD 27.14M 23.27M Jun/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Esperion Therapeutics USD -27.51M 9.5M Sep/2023
J&J USD 9.52B 389M Sep/2025
Knight Therapeutics CAD 15.51M 3.39M Jun/2025
Merck USD 8.39B 1.97B Sep/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novartis USD 5.88B 290M Sep/2025
Novartis USD 5.84B 235M Sep/2025
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 49.36M 4.96M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Supernus Pharmaceuticals USD 41.9M 432K Sep/2025
TG Therapeutics USD 37.7M 25.41M Jun/2025